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More than 600,000 head and neck cancers (HNC) are diag-
nosed every year and the incidence and mortality rates vary
according to the economical status of the country. Most
are oral, pharyngeal or laryngeal squamous cell carcinomas.
The most significant risk factors include lifestyle habits
(tobacco, alcohol drinking and diet). More recently, expo-
sure to some biological agents (HPV and EBV) and genetic
susceptibility were also identified. Tobacco smoking
increases acetaldehyde burden following alcohol consump-
tion, and alcohol consumption enhances the activation of
pro-carcinogens by induction of cytochrome P450-2E1 sys-
tem. HPV and EBV are associated with the oropharyngeal
and nasopharyngeal cancers, respectively. Genetic suscept-
ibility has a significant role in non-smoking young patients
and it is based on differences in the efficiencies of metabo-
lizing carcinogens, DNA repair and cell cycle control.
Familial aggregation of HNSCC has been recently reported
and the responsible genes are under investigation. Possibly,
the identification of a genetic risk profile may improve pre-
vention, early diagnosis and treatment. Most HNC are
characterized by local tumor invasion, frequent regional
lymph nodes metastasis, and multiple primary cancers in
the upper aerodigestive tract, esophagus and lung. Most
patients had advanced-stage disease at diagnosis and cur-
rent treatment options frequently incur significant morbid-
ity. The significant prognostic factors in HNC patients are
TNM stage, tumor site and histologic variables. However,
tumors of the same site with similar histology and stage
may behave differently due to their differing biological
characteristics. There is a major interest in the identifica-
tion of biomarkers (‘‘biological fingerprints”) that could be
used in the clinical practice in order to better prognosticate
and risk-stratify patients and predict treatment response.
The results of these investigations can completely change
clinical practice and result in effective “personalized
medicine”.
Only HPV positivity and EGFR overexpression are
currently considered reliable predictive markers for thera-
peutic response in HNC patients. Some recently published
studies have also shown that TP53 genetic polymorphisms
and mutations influence tumor progression and response
to therapy. Genotyping has being also utilized to probe
other known gene mutations and can offer potential for
identification and targeting of key pathways implicated in
tumor progression to guide therapeutic strategies. Recently
we have investigated the expression profile of Epithelial-
Mesenchymal-Transition genes in patients with oral SCC
using a cDNA microarray platform coupled to qRT-PCR
and immunohistochemical analysis. We identified TWIST1
transcription factor to be overexpressed and to predict
metastases and prognosis. Most prognostic information on
HNC are patient and tumor-related factors and occasion-
ally pathologic findings. These variables influence out-
comes prediction at diagnosis, but do not consider several
others such as response to initial therapy, complications,
risk of recurrences and second primary tumors. Further-
more, the risks of recurrence, second primary cancers and
non-cancer related deaths change during follow-up when a
patient develops a recurrence or second primary tumor.
More sophisticated prognostic evaluations are ongoing.
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